KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) EBIT Margin (2016 - 2025)

BeOne Medicines (ONC) has disclosed EBIT Margin for 11 consecutive years, with 12.35% as the latest value for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 1939.0% to 12.35% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.37%, a 2328.0% increase, with the full-year FY2025 number at 8.37%, up 2328.0% from a year prior.
  • EBIT Margin was 12.35% for Q4 2025 at BeOne Medicines, up from 11.55% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 89.06% in Q4 2021 to a low of 316.58% in Q2 2021.
  • A 5-year average of 59.87% and a median of 25.96% in 2023 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: surged 72953bps in 2021, then crashed -21235bps in 2022.
  • BeOne Medicines' EBIT Margin stood at 89.06% in 2021, then plummeted by -238bps to 123.29% in 2022, then surged by 51bps to 60.5% in 2023, then surged by 88bps to 7.04% in 2024, then surged by 275bps to 12.35% in 2025.
  • Per Business Quant, the three most recent readings for ONC's EBIT Margin are 12.35% (Q4 2025), 11.55% (Q3 2025), and 6.68% (Q2 2025).